Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

THRIL could be novel biomarker for immune activation, potential target for inflammatory diseases

Sanford-Burnham Medical Research Institute scientists have discovered a new molecule that forms when certain white blood cells-macrophages-are stimulated in response to pathogens.

27 Dec 2013

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist.

23 Dec 2013

European Commission approves update of Erbitux to treat patients with RAS wild-type mCRC

Merck Serono, the biopharmaceutical division of Merck, today announced that the European Commission has approved the Type II variation to amend the Erbitux(cetuximab) product information, updating the indication for Erbitux to the treatment of patients with RAS wild-type metastatic colorectal cancer (mCRC).

23 Dec 2013

Research proves effectiveness of computerized neurocognitive testing for concussions

Computerized neurocognitive testing for concussions is widely used in amateur and professional sports, but little research over the past decade proves its effectiveness, a paper published this month in the journal Neuropsychology Review says.

23 Dec 2013

Melanocyte-secreted fibromodulin promotes angiogenic microenvironment

The decreased vision loss that accompanies age-related macular degeneration (AMD) is associated with abnormal blood vessel growth in the eye. Frequencies of AMD development are different among racial backgrounds, with occurrence of AMD highest among individuals of mixed European decent.

22 Dec 2013

UC San Diego Sulpizio listed in “100 Hospitals with Great Heart Programs”

UC San Diego Sulpizio Cardiovascular Center (SCVC) has been featured in the latest Becker's Hospital Review list of "100 Hospitals with Great Heart Programs."

20 Dec 2013

UCD Conway Institute researchers identify potential biomarker of idiopathic pulmonary ﬁbrosis

Researchers in UCD Conway Institute have identified a potential biomarker of rapidly progressive pulmonary fibrosis and pinpointed a defective molecular function as a potential therapeutic target.

18 Dec 2013

Study provides important new perspective on how we look at bladder cancer biology

Bladder cancer will kill upward of 170,000 people worldwide this year, but bladder cancer isn't fatal in the bladder. Instead, in order to be fatal the disease must metastasize to faraway sites. The question has been this: does localized, non-muscle invasive bladder cancer eventually become the more dangerous, muscle-invasive form of the disease, or are NMI and MI bladder cancers genetically distinct from the start?

17 Dec 2013

Researchers use ATX-Red AR-2 as new imaging agent to illuminate tumors

Researchers from Echelon Biosciences, Inc. and collaborators from the University of Utah report the use of ATX-Red AR-2 as a new imaging agent that effectively illuminates tumors.

17 Dec 2013

arGEN-X reports that Phase Ib cancer study with ARGX-110 antibody meets translational development goals

arGEN-X announces that the dose-escalation part of a Phase Ib study with its lead antibody ARGX-110 has met its translational development goals: all pre-specified biological activity measures (e.g. target engagement, effector functions, immune-modulation) were met.

17 Dec 2013

Alnylam initiates Phase II study with ALN-TTRsc for treatment of ATTR

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated a pilot Phase II study with ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting the transthyretin gene in development for the treatment of TTR-mediated amyloidosis.

17 Dec 2013

Researchers identify potential biomarker to predict developmental problems in premature infants

Researchers have identified a potential biomarker for predicting whether a premature infant is at high risk for motor development problems, according to a study published online in the journal Radiology.

17 Dec 2013

New study aims to better understand brain aging and AD in adults with Down syndrome

To many, Down syndrome is a childhood condition. But improved health care means that individuals with DS now routinely reach age 50 or 60 years of age, sometimes beyond. However, if they live long enough, people with Down syndrome are almost certain to develop Alzheimer's disease.

17 Dec 2013

Scientists continue work to end chemotherapy pain

With this year's $600,000 grant from the Leukemia & Lymphoma Society and $1.5 million grant from the NIH, a Saint Louis University investigator is continuing her work to end chemotherapy pain. Noted pain researcher Daniela Salvemini, Ph.D., is using the funding to capitalize on her recent finding published in Pain, a breakthrough that helps scientists understand a molecular pathway by which pain occurs with certain anti-cancer drugs.

17 Dec 2013

Researchers identify first biomarker that appears to be associated with duration of delirium

Researchers from the Regenstrief Institute and the Indiana University Center for Aging Research have identified the first biomarker that appears to be linked to the duration of delirium.

16 Dec 2013

Researchers receive $6M grant to determine neuropathological condition of head injuries in non-athletes

Icahn School of Medicine at Mount Sinai researchers have been awarded a major federal grant to determine the long-term clinical and neuropathological sequelae of single and repeated head injuries in non-athletes.

16 Dec 2013

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

The I-SPY 2 trial, an innovative, multidrug, phase II breast cancer trial, has yielded positive results with the first drug to complete testing in the trial. Adding the chemotherapy carboplatin and the molecularly targeted drug veliparib to standard presurgery chemotherapy improved outcomes for women with triple-negative breast cancer, according to results from the I-SPY 2 trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

16 Dec 2013

Combination of ramucirumab and docetaxel fails to delay advanced breast cancer progression

Adding the antibody therapy ramucirumab to the chemotherapy drug docetaxel did not delay disease progression for patients with HER2-negative, advanced breast cancer, according to results of a placebo-controlled, randomized, phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

16 Dec 2013

Study shows effectiveness of PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced new results from a combined analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Trans-Arimidex, Tamoxifen, Alone or in Combination (TransATAC) studies. These results, which evaluated samples from 2,137 patients, suggest that the PAM50-based Prosignaz Breast Cancer Prognostic Gene Signature Assay may help identify women with late distant recurrence after five years of endocrine treatment.

13 Dec 2013

AVEO announces data from planned interim analysis of Phase 2 BATON study in CRC patients

AVEO Oncology today announced that data from a planned interim analysis of the Phase 2 BATON (Biomarker Assessment of Tivozanib in ONcology) study in patients with colorectal cancer (CRC) indicate that the study is unlikely to meet the primary endpoint in the intent-to-treat patient population.

13 Dec 2013

Biomarker News and Research

Further Reading

THRIL could be novel biomarker for immune activation, potential target for inflammatory diseases

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

European Commission approves update of Erbitux to treat patients with RAS wild-type mCRC

Research proves effectiveness of computerized neurocognitive testing for concussions

Melanocyte-secreted fibromodulin promotes angiogenic microenvironment

UC San Diego Sulpizio listed in “100 Hospitals with Great Heart Programs”

UCD Conway Institute researchers identify potential biomarker of idiopathic pulmonary ﬁbrosis

Study provides important new perspective on how we look at bladder cancer biology

Researchers use ATX-Red AR-2 as new imaging agent to illuminate tumors

arGEN-X reports that Phase Ib cancer study with ARGX-110 antibody meets translational development goals

Alnylam initiates Phase II study with ALN-TTRsc for treatment of ATTR

Researchers identify potential biomarker to predict developmental problems in premature infants

New study aims to better understand brain aging and AD in adults with Down syndrome

Scientists continue work to end chemotherapy pain

Researchers identify first biomarker that appears to be associated with duration of delirium

Researchers receive $6M grant to determine neuropathological condition of head injuries in non-athletes

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

Combination of ramucirumab and docetaxel fails to delay advanced breast cancer progression

Study shows effectiveness of PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay

AVEO announces data from planned interim analysis of Phase 2 BATON study in CRC patients

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News